Alvotech and Teva Secure US Settlement Date for AVT06 Biosimilar

Alvotech and Teva Pharmaceuticals have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), in the United States. The agreement grants a license entry date for AVT06 in the U.S. in the fourth quarter of 2026, or earlier under certain circumstances. AVT06 has received marketing approval in the UK, Japan, and the European Economic Area. The drug has shown high similarity to Eylea® in clinical studies. This settlement positions Alvotech and Teva for a successful U.S. market launch, pending FDA approval.